EQUITY CONSIDERATIONS IN THE CALCULATION OF COST-EFFECTIVENESS IN SUBSTANCE USE DISORDER POPULATIONS
Version of Record online: 6 OCT 2011
Addiction © 2011 Society for the Study of Addiction
Volume 106, Issue 11, pages 2047–2048, November 2011
How to Cite
GILMOUR, S. J. (2011), EQUITY CONSIDERATIONS IN THE CALCULATION OF COST-EFFECTIVENESS IN SUBSTANCE USE DISORDER POPULATIONS. Addiction, 106: 2047–2048. doi: 10.1111/j.1360-0443.2011.03606.x
- Issue online: 6 OCT 2011
- Version of Record online: 6 OCT 2011
- 3National Centre in HIV Epidemiology and Clinical Research (NCHECR). Return on Investment 2: evaluating the cost effectiveness of needle syringe programs in Australia: Department of Health and Ageing. Sydney, Australia: NCHECR; 2009.
- 4National Institute for Health and Clinical Excellence (NICE). Social Value Judgments: Principles for the Development of NICE Guidance, 2nd edn. London: NICE; 2008.